                         SEQUENCE LISTING

<110>  University of Bremen
 
<120>  Methods for enhanced cellular uptake of structures with a complex surface

<130>  UN15A20/P-WO

<160>  3     

<170>  PatentIn version 3.5

<210>  1
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PAR2 agonist peptide derived from rodent PAR2 TL


<220>
<221>  PEPTIDE
<222>  (1)..(6)
<223>  PAR2 agonist peptide derived from rodent PAR2 TL, wherein the 
       leucin at position 6 of the peptide is either modified with an 
       NH2 group or remains unmodified

<400>  1

Ser Leu Ile Gly Arg Leu 
1               5       


<210>  2
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Derivative of the PAR2 agonist peptide derived from rodent PAR2 
       TL


<220>
<221>  PEPTIDE
<222>  (1)..(5)
<223>  Derivative of the PAR2 agonist peptide derived from rodent PAR2 
       TL, wherein the leucin at position 5 of the peptide is either 
       modified with an NH2 group or remains unmodified and wherein the 
       leucin at position 1 of the peptide is modified with a 2-furoyl 
       

<400>  2

Leu Ile Gly Arg Leu 
1               5   


<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  PAR2 agonist peptide derived from human PAR2 TL


<220>
<221>  PEPTIDE
<222>  (1)..(6)
<223>  PAR2 agonist peptide derived from human PAR2 TL, wherein the 
       valine at position 6 of the peptide is either modified with an 
       NH2 group or remains unmodified

<400>  3

Ser Leu Ile Gly Lys Val 
1               5       


